Safety of parapulmonal application of xenon in the experiment
https://doi.org/10.35401/2541-9897-2022-25-3-52-57
Abstract
Pain syndrome is the most common reason for patients to seek medical care, the importance of which is steadily increasing in the structure of the total incidence. To optimize costs and ensure high-quality treatment of patients with chronic pain syndrome it is necessary to study existing drugs and methods and introduce new ones. Based on theoretical data on the use of inert gases in medicine, a hypothesis was put forward that xenon could have a pronounced analgesic effect when administered subcutaneously. This study is aimed at confirming the safety of xenon in parapulmonary administration to rats.
About the Authors
V. V. Khinovker
Federal Siberian Research Clinical Centre of the Federal Medical Biological Agency; Krasnoyarsk State Medical University named after Professor V.F. Voino-Yasenetsky
Russian Federation
Russian Federation
Vladimir V. Khinovker - Cand. Sci. (Med.), Head of the Department of Anesthesiology and Intensive Care, Federal Siberian Research Clinical Centre of the Federal Medical Biological Agency; Associate Professor, Department of Anesthesiology and Intensive Care IVE, Krasnoyarsk SMU named after Professor V.F. Voino-Yasenetsky.
1, Partisan Zheleznyaka str., Krasnoyarsk, 660022
O. F. Veselova
Krasnoyarsk State Medical University named after Professor V.F. Voino-Yasenetsky
Russian Federation
Russian Federation
Olga F. Veselova - Cand. Sci. (Med.), Head of the Department of Pharmacology and Clinical Pharmacology with a course of postgraduate education.
Krasnoyarsk
V. A. Koryachkin
Saint Petersburg State Pediatric Medical University
Russian Federation
Russian Federation
Viktor A. Koryachkin - Dr. Sci. (Med.), Professor of the Department of Anesthesiology, Resuscitation and Emergency Pediatrics.
Saint Petersburg
E. V. Khinovker
Krasnoyarsk State Medical University named after Professor V.F. Voino-Yasenetsky
Russian Federation
Russian Federation
Ekaterina V. Khinovker - Resident of the Department of Anes thesiology and Intensive Care IVE.
Krasnoyarsk
A. A. Gazenkampf
Krasnoyarsk Regional Clinical Hospital
Russian Federation
Russian Federation
Andrey A. Gazenkampf - Cand. Sci. (Med.), Associate Professor, Head of the Hospital Emergency Department.
Krasnoyarsk
References
1. Mills SEE, Nicolson KP, Smith BH. Chronic pain: A review of its epidemiology and associated factors in population-based studies. Br J Anaesth. 2019;123(2):273–283. PMID: 31079836. PMCID: PMC6676152. https://doi.org/10.1016/j.bja.2019.03.023
2. Larsson C, Hansson EE, Sundquist K, et al. Chronic pain in older adults: prevalence, incidence, and risk factors. Scand J Rheumatol. 2017;46(4);317–325. PMID: 27885914. https://doi.org/10.1080/03009742.2016.1218543
3. Gobina I, Villberg J, Välimaa R. Prevalence of self-reported chronic pain among adolescents: evidence from 42 countries and regions. Eur J Pain. 2019;23(2):316–326. PMID: 30098106. https://doi.org/10.1002/ejp.1306
4. Malon J, Shah P, Koh WY, et al. Characterizing the demographics of chronic pain patients in the state of Maine using the Maine all payer claims database. BMC Public Health. 2018;18(1):810. PMID: 29954350. PMCID: PMC6022454. https://doi.org/10.1186/s12889-018-5673-5
5. Maly A, Vallerand AH. Neighborhood, socioeconomic, and racial influence on chronic pain. Pain Manag Nurs. 2018;19:14– 22. PMID: 29422123. PMCID: PMC8895435. https://doi.org/10.1016/j.pmn.2017.11.004
6. Cavalli E, Mammana S, Nicoletti F, et al. The neuropathic pain: An overview of the current treatment and future therapeutic approaches. Int J Immunopathol Pharmacol. 2019;33:2058738419838383. PMID: 30900486. PMCID: PMC5431761. https://doi.org/10.1177/2058738419838383
7. Thomson SJ, Tavakkolizadeh M, Love-Jones S. Effects of rate on analgesia in kilohertz frequency spinal cord stimulation: Results of the PROCO randomized controlled trial. Neuromodulation. 2018;21(1):67–76. PMID: 29220121. PMCID: PMC5814855. https://doi.org/10.1111/ner.12746
8. Dones I, Levi V. Spinal Cord Stimulation for Neuropathic Pain: Current Trends and Future Applications. Brain Sci. 2018;8(8):138. PMID: 30042314. PMCID: PMC6119923. https://doi.org/10.3390/brainsci8080138
9. Stewart K. Recent advances in the management of chronic pain. Prescriber. 2017;(28):2. https://doi.org/10.1002/psb.1542
10. Meske DS, Lawal OD, Elder H, et al. Efficacy of opioids versus placebo in chronic pain: a systematic review and meta-analysis of enriched enrollment randomized withdrawal trials. J Pain Res. 2018;11:923–934. PMID: 29765246. PMCID: PMC5939920. https://doi.org/10.2147/jpr.s160255
11. Richebé P, Rivat C, Creton C, et al. Nitrous oxide revisited: evidence for potent antihyperalgesic properties. Anesthesiology. 2005;103(4):845–854. PMID: 16192778. https://doi.org/10.1097/00000542-200510000-00024
12. Giacalone M, Abramo A, Giunta F, et al. Xenon-related analgesia: a new target for pain treatment. Clin J Pain. 2013;29(7):639–643. PMID: 23328329. https://doi.org/10.1097/ajp.0b013e31826b12f5
13. Mendes FF, Gomes ME. Xenon: pharmacology and clinical use. Rev Bras Anestesiol. 2003;53(4):535–542. PMID: 19475306.
14. Nazarov I.P. Ozone, xenon and ozone-xenon therapy. Bioradicals and antioxidants. 2016;3(2):74–152. (In Russ.).
15. Abrashova TV, Sokolova AP, Selezneva AI, et al. Variability of biochemical and hematological parameters in laboratory rats depending on the line and age. International Bulletin of Veterinary Medicine. 2010;2:55–60. (In Russ.).
Review
For citations:
Khinovker V.V., Veselova O.F., Koryachkin V.A., Khinovker E.V., Gazenkampf A.A. Safety of parapulmonal application of xenon in the experiment. Innovative Medicine of Kuban. 2022;(3):52-57. (In Russ.) https://doi.org/10.35401/2541-9897-2022-25-3-52-57
Views:
316
Email this article 
